Developing a broad and differentiated portfolio of drug candidates to address unmet needs within and beyond psychiatry
Psychiatry
Our psychiatric pipeline features a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment alternative for depression, and ultimately, to address a broad range of unmet needs
| Program | Indication | Phase I | Phase II | Phase II | Phase I | Milestone |
|---|---|---|---|---|---|---|
| ELE-Psilo | Depression | Phase I Initiation 1H 2022 | ||||
Beyond Psychiatry
Eleusis is exploring the exciting potential of psychedelics beyond psychiatry - as immunomodulatory and neuroprotective medicines. These and other areas are detailed in Science. Welcome to the clinical evolution of psychedelics.